Eltrombopag. Coated tablets
ELOPAG®:Packages containing 28 coated tablets.
ELOPAG® is indicated for the treatment of patients aged 1 year and above with primary chronic immune thrombocytopenia (idiopathic) (ITP) who are refractory to other treatments (e.g. corticosteroids, immunoglobulins).
ELOPAG®is indicated in adult patients with chronic hepatitis C virus (HCV) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy.
ELOPAG®is indicated in adult patients with acquired severe aplastic anaemia (SAA) who were either refractory to prior immunosuppressive therapy or heavily pretreated and are unsuitable for haematopoietic stem cell transplantation.
Dose and Administration
Chronic Immune (primary) thrombocytopenia: Adults and paediatric population aged 6 to 17 years: The recommended starting dose of ELOPAG® is 50 mg once daily. Paediatric population aged 1 to 5 years: The recommended starting dose of ELOPAG® is 25 mg once daily.
Chronic hepatitis C (HCV) associated thrombocytopenia: The recommended starting dose of ELOPAG® is 25 mg once daily.
Severe aplastic anaemia: The recommended starting dose of ELOPAG® 50 mg once daily.
For monitoring, dose adjustment or treatment suspension criteria, for all indications, please, consult the complete product leaflet.
Store at room temperature below 25ºC, in it original package.